MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)。

BAY1125976

CAS No. : 1402608-02-9

MCE 國(guó)際站：BAY1125976

產(chǎn)品活性：BAY1125976 是 Akt1/Akt2 選擇性的變構(gòu)抑制劑；在10 μM ATP 時(shí)抑制 Akt1 和 Akt2 活性的 IC₅₀值分別為 5.2 nM 和 18 nM。

研究領(lǐng)域：PI3K/Akt/mTOR

作用靶點(diǎn)：Akt

In Vitro: BAY 1125976 is equally potent against Akt1 (IC₅₀=5.2 nM at 10 μM ATP and 44 nM at 2 mM ATP) and Akt2 (IC₅₀=18 nM at 10 μM ATP and 36 nM at 2 mM ATP) isoforms and up to 86 fold less potent against Akt3 (IC₅₀=427 nM at 10 μM ATP). It inhibits the Akt1 and Akt2 by binding into an allosteric binding pocket formed by kinase and PH domain. It inhibits cell proliferation in a broad panel of human cancer cell lines, particularly in breast and prostate cancer cell lines expressing estrogen or androgen receptors. It effectively blocks Akt signaling by inhibiting the phosphorylation of Akt and the downstream effectors, including eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1), glycogen synthase kinase 3 beta (GSK3s), proline-rich Akt substrate 40 kDa (PRAS40), S6 ribosomal protein (S6RP), and 70 kDa ribosomal protein S6 kinase 1 (70S6K).

In Vivo: BAY 1125976 targets tumors displaying activation of the PI3K/Akt/mTOR pathway. BAY 1125976 exhibits strong in vivo efficacy in both cell line and patient-derived xenograft models such as the KPL4 breast cancer model (PIK3CA^H1074R mutant), the MCF7 and HBCx-2 breast cancer models, and the Akt^E17K mutant driven prostate cancer (LAPC-4) and anal cancer (AXF 984) models.

相關(guān)產(chǎn)品：Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Kinase Inhibitor Library  |  PI3K/Akt/mTOR Compound Library  |  Stem Cell Signaling Compound Library  |  Anti-Cancer Compound Library  |  Clinical Compound Library  |  Autophagy Compound Library  |  Anti-Aging Compound Library  |  Differentiation Inducing Compound Library  |  Oxygen Sensing Compound Library  |  Glycolysis Compound Library  |  Cytoskeleton Compound Library  |  Chemical Probe Library  |  Glutamine Metabolism Compound Library  |  Anti-Breast Cancer Compound Library  |  Anti-Lung Cancer Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Blood Cancer Compound Library  |  Anti-Cancer Metabolism Compound Library  |  Anti-Obesity Compound Library  |  Angiogenesis-Related Compound Library  |  Glucose Metabolism Compound Library  |  Targeted Diversity Library  |  Anti-Liver Cancer Compound Library   |  Anti-Colorectal Cancer Compound Library   |  Anti-Prostate Cancer Compound Library  |  Anti-Pulmonary Fibrosis Compound Library  |  Cancer Stem Cells Compound Library  |  Pain-Related Compound Library  |  Membrane Protein-targeted Compound Library  |  Highly Selective Inhibitors Library  |  Serine/Threonine Kinase Inhibitor Library  |  LM22B-10  |  Insulin Detemir  |  (rac)-AG-205  |  Multi-kinase-IN-2  |  Akt/SKG Substrate Peptide  |  AS1949490  |  1,3-Dicaffeoylquinic acid  |  Threo-Chloramphenicol-d₆  |  AKT-IN-14  |  NSC45586  |  APN/AKT-IN-1  |  MS5033  |  Sophocarpine monohydrate  |  MS143  |  Deferoxamine  |  Chaetominine  |  Hu7691 free base  |  AKT-IN-3  |  8-Aminoadenosine  |  Nrf2/HO-1 activator 2  |  AT13148  |  Pachymic acid  |  Polygalasaponin F  |  Akt1&PKA-IN-1  |  Triciribine  |  PI3K-IN-29  |  Oxaprozin  |  CCT128930  |  YS-49

熱門產(chǎn)品線：重組蛋白  |  化合物庫(kù)  |  天然產(chǎn)物  |  熒光染料  |  PROTAC  |  同位素標(biāo)記物  |  寡核苷酸  |  抗體  |  點(diǎn)擊化學(xué)

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry